Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients

Thursday, August 26, 2010 Heart Disease News
Email Print This Page Comment
Font : A-A+

Following Positive Results in Phase I/IIa Dose-Escalation Trial, Cardioxyl Continues to Evaluate Clinical Safety and Tolerability of CXL-1020

(i) Heart Disease and Stroke Statistics 2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119:e1-e161

(ii) Gheorghiade, M. Reassessing treatment of acute heart failure syndromes: the ADHERE Registry. Eur Heart J Suppl.  2005  7: B13-B19

(iii) Jong, P et al. Prognosis and Determinants of Survival in Patients Newly Hospitalized for Heart Failure. Arch Int Med, 2002; 162:1689-1694



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook